Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

Sambavy Nadaraja; Aissata Diop Mamoudou; Harald Thomassen; Peder Skov Wehner; Steen Rosthoej; Henrik Schroeder

doi:10.1002/pbc.24068

Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

Sambavy Nadaraja, Aissata Diop Mamoudou, Harald Thomassen, Peder Skov Wehner, Steen Rosthoej, Henrik Schroeder

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

13 Citationer (Scopus)

Abstract

High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic. First generation 5-HT(3) receptor antagonists are effective prophylactic agents but require multiple administrations. Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor. Adult studies have demonstrated that palonosetron is both more effective and require fewer administrations than first generation 5-HT(3) receptor antagonists. The purpose of this study was to examine the effect of a single dose of palonosetron (5 µg/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).

Originalsprog	Engelsk
Tidsskrift	Pediatric Blood & Cancer
Vol/bind	59
Sider (fra-til)	870-3
Antal sider	4
ISSN	1545-5009
DOI	https://doi.org/10.1002/pbc.24068
Status	Udgivet - 2012
Udgivet eksternt	Ja

Adgang til dokumentet

10.1002/pbc.24068

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

@article{c123cba72af043248b29dfa7b5901cbc,

title = "Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate",

abstract = "High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic. First generation 5-HT(3) receptor antagonists are effective prophylactic agents but require multiple administrations. Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor. Adult studies have demonstrated that palonosetron is both more effective and require fewer administrations than first generation 5-HT(3) receptor antagonists. The purpose of this study was to examine the effect of a single dose of palonosetron (5 µg/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).",

keywords = "Adolescent, Adult, Antimetabolites, Antineoplastic, Child, Child, Preschool, Denmark, Female, Humans, Isoquinolines, Male, Methotrexate, Nausea, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Quinuclidines, Serotonin Antagonists, Time Factors, Vomiting",

author = "Sambavy Nadaraja and Mamoudou, {Aissata Diop} and Harald Thomassen and Wehner, {Peder Skov} and Steen Rosthoej and Henrik Schroeder",

note = "Copyright {\textcopyright} 2012 Wiley Periodicals, Inc.",

year = "2012",

doi = "10.1002/pbc.24068",

language = "English",

volume = "59",

pages = "870--3",

journal = "Pediatric Blood & Cancer",

issn = "1545-5009",

publisher = "Wiley",

}

TY - JOUR

T1 - Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

AU - Nadaraja, Sambavy

AU - Mamoudou, Aissata Diop

AU - Thomassen, Harald

AU - Wehner, Peder Skov

AU - Rosthoej, Steen

AU - Schroeder, Henrik

PY - 2012

Y1 - 2012

N2 - High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic. First generation 5-HT(3) receptor antagonists are effective prophylactic agents but require multiple administrations. Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor. Adult studies have demonstrated that palonosetron is both more effective and require fewer administrations than first generation 5-HT(3) receptor antagonists. The purpose of this study was to examine the effect of a single dose of palonosetron (5 µg/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).

AB - High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic. First generation 5-HT(3) receptor antagonists are effective prophylactic agents but require multiple administrations. Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor. Adult studies have demonstrated that palonosetron is both more effective and require fewer administrations than first generation 5-HT(3) receptor antagonists. The purpose of this study was to examine the effect of a single dose of palonosetron (5 µg/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).

KW - Adolescent

KW - Adult

KW - Antimetabolites, Antineoplastic

KW - Child

KW - Child, Preschool

KW - Denmark

KW - Female

KW - Humans

KW - Isoquinolines

KW - Male

KW - Methotrexate

KW - Nausea

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Quinuclidines

KW - Serotonin Antagonists

KW - Time Factors

KW - Vomiting

U2 - 10.1002/pbc.24068

DO - 10.1002/pbc.24068

M3 - Journal article

SN - 1545-5009

VL - 59

SP - 870

EP - 873

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

ER -

Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

Abstract

Adgang til dokumentet

AUB Link

Fingeraftryk

Citationsformater